21st Century Cancer Care: Will New Models Lead to Better Care at Lower Cost?
On November 7, ThinkAnthem and Alliance for Health Reform hosted a Capitol Hill briefing on innovative cancer care programs reshaping the current oncology care delivery and payment structure.
The Current Landscape
According to the Institute of Medicine, the demand for cancer care will continue to grow in the coming years. In the US alone:
- More than 1.6 million new cases are diagnosed each year;
- It is projected that there will be 18 million cancer survivors by 2022; and
- Cancer incidence is expected to rise to 2.3 million new diagnoses per year by 2030.
Achieving high-quality cancer care in the context of rising costs presents a challenge to our health care system, patients and their loved ones. The current system for ordering and reimbursing for oncology drugs, which incentivizes the use of more expensive medicines, further contributes to high costs – and more expensive drugs are not necessarily more effective for patients. Moreover, research suggests that patients do not always receive evidence-based cancer care.
This briefing will present an overview of the current challenges facing patients and oncologists as they weigh the benefits and costs of different treatment options and will highlight some of the approaches being implemented across the country to deliver high-value cancer care.
The session will be moderated by AHR Vice President of Policy, Sarah Dash, and speakers will include:
- Dr. Deborah Schrag, Professor of Medicine, Harvard Medical School; Chief, Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute
- Shelley Fuld Nasso, CEO, National Coalition for Cancer Survivorship
- Dr. Jennifer Malin, Medical Director for Oncology and Care Management, Anthem Inc.
- Dr. Nancy Davidson, Director, University of Pittsburgh Cancer Institute (UPCI)